Select a State

Global health R&D delivers for Minnesota

US government investment in global health R&D has delivered

$32.8 million
to Minnesota research institutions
400+ new jobs
for Minnesota

Neglected diseases in Minnesota

Chikungunya cases
59
Dengue cases
104
HIV diagnoses
2,854
Malaria cases
358
Tuberculosis cases
1,422
West Nile cases
286
Zika cases
74

Minnesota's top USG-funded global health R&D institutions

University of Minnesota
$32.8 million

Minnesota industry in global health R&D

3M
Location(s):
Saint Paul
Beckman Coulter
Location(s):
Chaska
GeneSegue
Location(s):
Minnetonka
Medical Avatar
Location(s):
Minneapolis
Medisyn Technologies
Location(s):
Minnetonka
Medtronic
Location(s):
Minneapolis

Minnesota's top areas of global health R&D by USG funding

26.9%
HIV/AIDS
25.2%
Malaria
16.0%
Tuberculosis
3.0%
Diarrheal diseases
24.7%
Salmonella infections
2.0%
Cryptococcal meningitis
2.3%
Other
Bacteria pneumonia & meningitis
Ebola/viral hemorrhagic fevers

Global health R&D at work in Minnesota

Researchers at the University of Minnesota Medical School are working to unlock why antiretroviral therapies are unable to completely shut down HIV production in cells in certain parts of the body. According to their research, nearly 99 percent of these HIV-infected cells are found in tissue in the lymph nodes, spleen, and gastrointestinal tract. This reservoir of latently infected cells can reactivate if therapy is interrupted, posing a major challenge to curing the disease. Their key finding was that these cells are associated with lower concentrations of drugs in these tissues. A next step is to understand why current treatments do not reach adequate levels in lymphoid tissue. This knowledge could lead to development of more effective treatments for HIV or even a cure for AIDS. Globally, more than 36 million people are living with HIV.

Footnotes